The global liquid biopsy market is predicted to reach US$ 13.72 Billion by 2031, from US$ 3.94 Billion in 2023. Liquid biopsy is a non-invasive technology that detects molecular biomarkers using liquid samples without the need for costly or invasive procedures. Liquid biopsy tests are executed to understand the molecular aspects of cancer across healthcare and research settings, such as hospitals, physicians, pathological and research laboratories. The advantages of liquid biopsy over solid tumor biopsy, the rising prevalence of cancer, increasing preference for non-invasive procedures, growing public and private funding to support research activities in the field of liquid biopsy and favorable government initiatives, are some of the factors expected to propel market growth over the forecast period.
The liquid biopsy market is a rapidly growing sector with numerous companies focusing on scientific advancements. For instance, in November 2023, Illumina Inc. announced TruSight Oncology 500 ctDNA v2, an advanced iteration of its liquid biopsy assay designed for comprehensive genomic profiling in oncology. This upgraded version promises enhanced sensitivity and specificity in detecting cancer-associated mutations from circulating tumor DNA. Further, in November 2023, Foundation Medicine, Inc., and Pierre Fabre Laboratories announced a collaboration to develop Foundation Medicine’s high-quality genomic tests, FoundationOne CDx and FoundationOne Liquid CDx, as companion diagnostics for new targeted therapies to treat patients with non-small cell lung cancer (NSCLC).
Recent Developments
In January 2024, Guardant Health, Inc. and Hikma Pharmaceuticals PLC, announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in countries across the Middle East and North Africa (MENA).
In November 2023, Foundation Medicine, Inc., and Pierre Fabre Laboratories announced a collaboration to develop Foundation Medicine’s high-quality genomic tests, FoundationOne CDx and FoundationOne Liquid CDx, as companion diagnostics for new targeted therapies to treat patients with non-small cell lung cancer (NSCLC).
In July 2023, MiRXES raised US$ 50 Million in series D venture funding for the development and commercialization of liquid biopsy products targeting colorectal cancer and the multi-cancer early detection test.
In May 2023, Labcorp, a leading global life sciences company, launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted therapy selection for patients with advanced or metastatic solid tumors.
By Circulating Biomarker: Global Liquid Biopsy Market and Forecast - Key Takeaways
Based on circulating biomarkers, the circulating tumor cells (CTCs) segment dominated the global liquid biopsy market in 2023.
The circulating tumor DNA (ctDNA) is the second largest segment of the liquid biopsy market capturing over a quarter share in 2023.
The extracellular vesicles (EVs) are expected to be the fastest-growing segment in the circulating biomarkers market over the forecast period.
By Products: Global Liquid Biopsy Market and Forecast - Key Takeaways
Based on product, the Kits and Consumables segment accounted for the largest share of the liquid biopsy market in 2023.
The instruments segment is likely to witness the fastest growth in the global liquid biopsy market over the forecast period.
The services segment captured the least share of the global liquid biopsy market.
By Application: Global Liquid Biopsy Market and Forecast - Key Takeaways
The global liquid biopsy market, by application, is being dominated by the oncology segment. Lung cancer and breast cancer accounted for the largest share of the liquid biopsy oncology market. Together, they controlled approx. 42% share of the liquid biopsy oncology market in 2023.
The non-cancer application is expected to be the fastest-growing segment in the market over the forecast period. Among non-cancer applications, Non-invasive prenatal testing (NIPT) dominated the market.
By Clinical Application: Global Liquid Biopsy Oncology Market and Forecast - Key Takeaways
Based on clinical application, the therapy selection segment dominated the global liquid biopsy market in 2023, and is expected to lead the market over the forecast period.
Treatment monitoring captured the second-highest share of the liquid biopsy market in 2023, followed by the early cancer screening application.
Recurrence monitoring captured the least share of the liquid biopsy market.
By End User: Global Liquid Biopsy Market and Forecast - Key Takeaways
Reference laboratories form the largest and fastest-growing end-user segment of the liquid biopsy market.
Hospital and Physician laboratories occupied the second-highest share of the liquid biopsy market in 2023, followed by Academic and Research Centers.
By Sample Type: Global Liquid Biopsy Market and Forecast - Key Takeaways
Blood is the most widely used sample type and is expected to remain the largest market over the forecast period as well.
The urine sample segment is anticipated to witness noticeable growth over the forecast period.
By Region: Global Liquid Biopsy Market and Forecast - Key Takeaways
North America accounted for the largest share of the global liquid biopsy market in 2023, followed by Europe.
In Europe, Germany and France are the leading markets for liquid biopsy.
Asia Pacific is the fastest-growing market for liquid biopsy. In Asia Pacific, Japan and China are the leading markets for liquid biopsy. China represents a huge opportunity for the liquid biopsy market because of increased market access of the country’s population to healthcare resources.
South America and Middle East & Africa are competing closely to grab the maximum share of the global liquid biopsy market.
This report provides a comprehensive assessment of the fast-evolving, high-growth Global Liquid Biopsy Market.
This 607 Pages report with 130 Figures and 9 Tables has been analyzed from 16 viewpoints:
1. Global Liquid Biopsy Market & Forecast (2018 - 2031)
2. Global Liquid Biopsy Market Share & Forecast (2018 - 2031)
3. Global Liquid Biopsy Market & Forecast - by Circulating Biomarker (2018 - 2031)
4. Global Liquid Biopsy Market & Forecast - by Product (2018 - 2031)
5. Global Liquid Biopsy Market & Forecast - by Application (2018 - 2031)
6. Global Liquid Biopsy Oncology Market & Forecast - By Cancer Types (2018 - 2031)
7. Global Liquid Biopsy Non-Cancer Application Market & Forecast - By Types (2018 - 2031)
8. Global Liquid Biopsy Oncology Market & Forecast - by Clinical Application (2018 - 2031)
9. Global Liquid Biopsy Market & Forecast - by End User (2018 - 2031)
10. Global Liquid Biopsy Market & Forecast - by Sample Type (2018 - 2031)
11. Liquid Biopsy Market & Forecast - Regional Analysis (2018 - 2031)
12. Liquid Biopsy Market Share & Forecast - Country Analysis (2018 - 2031)
13. Liquid Biopsy Initiatives
14. Liquid Biopsy Companies Financing Details
15. 35 Company Profiles - Recent Developments / Initiatives, Major Deals
16. Global Liquid Biopsy Market - Driving Factors & Challenges
By Circulating Biomarker: Global Liquid Biopsy Market and Forecast
1. Circulating Tumor Cells (CTCs)
2. Circulating Tumor DNA (ctDNA)
3. Cell-Free DNA (cfDNA)
4. Extracellular Vesicles (EVs)
5. Other Circulating Biomarkers
By Product: Global Liquid Biopsy Market and Forecast
1. Kits and Consumables
2. Instruments
3. Services
By Application: Global Liquid Biopsy Market and Forecast
1. Oncology Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastrointestinal Cancer
- Leukaemia
- Others
2. Non-Cancer Application
- Non-Invasive Prenatal Testing (NIPT)
- Organ Transplantation
- Infectious Disease Testing
By Clinical Application: Global Liquid Biopsy Market and Forecast
1. Therapy Selection
2. Treatment Monitoring
3. Early Cancer Screening
4. Recurrence Monitoring
By End User: Global Liquid Biopsy Market and Forecast
1. Reference Laboratories
2. Hospitals and Physician Laboratories
3. Academic and Research Centers
4. Other End Users
By Sample Type: Global Liquid Biopsy Market and Forecast
1. Blood Sample
2. Urine Sample
3. Other Fluids Sample
By Region: Global Liquid Biopsy Market and Forecast
1. North America
- United States
- Canada
- Mexico
2. Asia Pacific
- South Korea
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
3. Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Rest of Europe
4. Middle East & Africa
- UAE
- Saudi Arabia
- Egypt
- Rest of the Middle East & Africa
5. South America
- Brazil
- Argentina
- Rest of South America
Global Liquid Biopsy Market - Company Profiles, Recent Developments, Major Deals
1. Personal Genome Diagnostics (Acquired by Labcorp)
2. Guardant Health, Inc.
3. Pathway Genomics (Now OME CARE)
4. RainDance Technologies (Acquired by Bio-Rad Laboratories, Inc.)
5. Cardiff Oncology (Previously Trovagene, Inc.)
6. LungLife AI (Formerly Cynvenio Biosystems, Inc.)
7. Biocept, Inc.
8. ANGLE plc
9. MDxHealth
10. Biolidics Limited (Formerly Clearbridge Biomedics Pte Ltd)
11. Exosome Diagnostics, Inc. (Acquired by Bio-Techne Corporation)
12. Foundation Medicine, Inc
13. Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche AG)
14. Genomic Health (Now Part of Exact Sciences Corp)
15. Myriad Genetics, Inc
16. Thermo Fisher Scientific, Inc
17. QIAGEN NV
18. Bio-Rad Laboratories, Inc
19. Menarini-Silicon Biosystems
20. GRAIL
21. NeoGenomics, Inc.
22. DiaCarta, Inc.
23. OncoCell MDx (Now Immunis.AI)
24. C2i Genomics (Acquired by Veracyte, Inc.)
25. Biodesix
26. Freenome
27. Inivata
28. CellMax Life
29. Rarecyte Inc.
30. Saga Diagnostics
31. Thrive Earlier Detection Corp. (Acquired by Exact Sciences Corp.)
32. Lucence Diagnostics Pte Ltd
33. Karius, Inc.
34. Clinical Genomics Technologies Pty Ltd (CG)
35. Elypta
Data Sources
The publisher employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from the Proprietary Information Database, Primary and Secondary Research Methodologies, and In-house analysis a dedicated team of qualified professionals with deep industry experience and expertise.
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interviews, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Reports, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.
Table of Contents
1. Executive Summary2. Global Liquid Biopsy Market & Forecast (2018 - 2031)
Companies Mentioned
- ANGLE plc
- Bio-Rad Laboratories, Inc
- Biocept, Inc.
- Biodesix
- Biolidics Limited (Formerly Clearbridge Biomedics Pte Ltd)
- C2i Genomics (Acquired by Veracyte, Inc.)
- Cardiff Oncology (Previously Trovagene, Inc.)
- CellMax Life
- Clinical Genomics Technologies Pty Ltd (CG)
- DiaCarta, Inc.
- Elypta
- Exosome Diagnostics, Inc. (Acquired by Bio-Techne Corporation)
- Foundation Medicine, Inc
- Freenome
- Genomic Health (Now Part of Exact Sciences Corp)
- GRAIL
- Guardant Health, Inc.
- Inivata
- Karius, Inc.
- Lucence Diagnostics Pte Ltd
- LungLife AI (Formerly Cynvenio Biosystems, Inc.)
- MDxHealth
- Menarini-Silicon Biosystems
- Myriad Genetics, Inc
- NeoGenomics, Inc.
- OncoCell MDx (Now Immunis.AI)
- Pathway Genomics (Now OME CARE)
- Personal Genome Diagnostics (Acquired by Labcorp)
- QIAGEN NV
- RainDance Technologies (Acquired by Bio-Rad Laboratories, Inc.)
- Rarecyte Inc.
- Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche AG)
- Saga Diagnostics
- Thermo Fisher Scientific, Inc
- Thrive Earlier Detection Corp. (Acquired by Exact Sciences Corp.)
